NYMOX PHARMACEUTICAL CORPORATION Equity
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) had Equity of -$6.78 million as of 2024-12-31, per its 20-F filed 2025-06-03.
Financial Statements › Notes
ifrs-full:Equity · last filed 2025-06-03
- 2024-12-31: Equity -$6.78M.
- 2024-09-30: Equity -$6.30M.
- 2023-12-31: Equity -$3.17M.
- 2023-09-30: Equity -$1.90M.
| Period end | Equity | Equity as first filed |
|---|---|---|
| 2024-12-31 | -$6.78M 20-F · filed 2025-06-03 | |
| 2024-09-30 | -$6.30M 6-K · filed 2025-01-02 | |
| 2023-12-31 | -$3.17M 20-F · filed 2025-06-03 | |
| 2023-09-30 | -$1.90M 6-K · filed 2025-01-02 | |
| 2023-06-30 | -$2.88M 6-K · filed 2023-08-14 | |
| 2023-03-31 | -$1.80M 6-K · filed 2023-05-12 | |
| 2022-12-31 | -$482.00K 20-F · filed 2025-06-03 | |
| 2022-09-30 | $773.00K 6-K · filed 2023-11-15 | |
| 2022-06-30 | $2.23M 6-K · filed 2023-08-14 | |
| 2022-03-31 | -$1.39M 6-K · filed 2023-05-12 | |
| 2021-12-31 | -$506.00K 20-F · filed 2025-06-03 | |
| 2021-09-30 | $1.58M 6-K/A · filed 2022-11-16 | |
| 2021-06-30 | $4.71M 6-K · filed 2022-08-15 | |
| 2021-03-31 | -$12.00K 6-K · filed 2022-05-13 | |
| 2020-12-31 | $2.15M 20-F · filed 2024-08-29 | |
| 2020-09-30 | $38.44M 6-K · filed 2021-11-12 | $3.84M 6-K · filed 2020-11-13 |
| 2020-06-30 | -$1.06M 6-K · filed 2021-08-13 | |
| 2020-03-31 | $1.44M 6-K · filed 2021-05-14 | |
| 2019-12-31 | $3.45M 20-F · filed 2023-05-02 | |
| 2019-09-30 | $5.65M 6-K · filed 2020-11-13 | |
| 2019-06-30 | $7.57M 6-K · filed 2020-08-14 | |
| 2019-03-31 | $10.09M 6-K · filed 2020-05-14 | |
| 2018-12-31 | $7.00M 20-F · filed 2022-03-30 | |
| 2018-09-30 | $3.93M 6-K · filed 2019-11-13 | |
| 2018-06-30 | $3.55M 6-K · filed 2018-08-13 | |
| 2018-03-31 | -$1.04M 6-K · filed 2018-05-15 | |
| 2017-12-31 | -$1.25M 20-F · filed 2021-03-29 | |
| 2016-12-31 | -$241.00K 20-F · filed 2020-03-30 | |
| 2015-12-31 | -$2.35M 20-F · filed 2019-03-29 | |
| 2014-12-31 | -$3.78M 20-F · filed 2018-03-30 |